ANBL1232: Utilizing Response and Biology Risk Factors to guide Therapy in Patients with Non-Risks Neuroblastoma

This phase III study is looking at whether using certain risk factors and biomarkers (proteins and/or gene changes in tumor cells) to determine how much treatment a younger patient with non-high risk neuroblastoma should receive will allow for a decrease in treatment for these patients while still curing their neuroblastoma. For some patients, this may include no treatment and only close observation. Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and what the best treatment is. This may help to avoid some of the risks and side effects related to standard treatment.

Are you Eligible? (Inclusion Criteria)

• Patients must be less than 18 months old.
• Patients must be newly diagnosed with non-high risk neuroblastoma.
• Patients must have had no prior radiotherapy or chemotherapy, with the exception of dexamethasone.
• Patients must also meet all eligibility criteria as outlined in the study protocol.